Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?
- 1 July 2005
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 92 (1), 95-96
- https://doi.org/10.1007/s10549-005-1942-y
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Adefovir Dipivoxil for Chemotherapy-Induced Activation of Hepatitis B Virus InfectionNew England Journal of Medicine, 2005
- Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2004
- Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administrationLiver International, 2004
- High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapyJournal of Viral Hepatitis, 2004
- Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapyGastroenterology, 2003
- Hepatitis B Reactivation in Patients Positive for Hepatitis B Surface Antigen Undergoing Autologous Hematopoietic Cell TransplantationLeukemia & Lymphoma, 2003
- High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantationBlood, 2002
- Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patientsCancer, 2001
- Hepatitis B virus reactivation during cytotoxic chemotherapy‐enhanced viral replication precedes overt hepatitisJournal of Medical Virology, 2001